Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02327273 · ClinicalTrials.gov registry record · Phase 1
Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT02327273 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 88 participants.
The verdict
NCT02327273, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety profile, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) following single and multiple oral doses of BMS-963272 in healthy subjects.
Interventions
- DRUG Placebo
- DRUG BMS-963272
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02327273
The ClinicalTrials.gov registry entry for NCT02327273 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02327273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02327273 about?
NCT02327273 is a clinical study titled "Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects". The purpose of this study is to evaluate the safety profile, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) following single and multiple oral doses of BMS-963272 in healthy subjects.
What is the current status of trial NCT02327273?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2014-10. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02327273?
The interventions under investigation include: Placebo (DRUG), BMS-963272 (DRUG).
Who is sponsoring clinical trial NCT02327273?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.